This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...
One of the best ways to improve the customer’s shopping experience is with package inserts; customer package inserts can be designed to improve the customer’s unpackaging experience greatly, which in ...
EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...
“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...
NEW YORK – The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday said it would recommend marketing authorization for Novartis' CDK4/6 inhibitor Kisqali ...
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...
Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, the FDA said Monday. … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback